Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer

Acta Oncol. 2014 Oct;53(10):1440-5. doi: 10.3109/0284186X.2014.921727. Epub 2014 Jul 3.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Cyclophosphamide / administration & dosage
  • Docetaxel
  • Doxorubicin / administration & dosage
  • Doxorubicin / analogs & derivatives
  • Drug Administration Schedule
  • Feasibility Studies
  • Female
  • Humans
  • Middle Aged
  • Neoadjuvant Therapy / methods*
  • Polyethylene Glycols / administration & dosage
  • Receptor, ErbB-2 / analysis
  • Receptors, Estrogen / analysis
  • Sample Size
  • Taxoids / administration & dosage
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • Receptors, Estrogen
  • Taxoids
  • liposomal doxorubicin
  • Docetaxel
  • Polyethylene Glycols
  • Doxorubicin
  • Cyclophosphamide
  • Receptor, ErbB-2
  • Trastuzumab

Associated data

  • ClinicalTrials.gov/NCT01206881